Consolidation Of Xarelto Lawsuit Cases Occurs As Concern Over Drug Side Effects Grows

June 21, 2016 – – TheProductLawyers.com announces the mounting public concern over the safety of the anticoagulant drug, Xarelto. While the FDA approved its use in 2011, it has since become the subject of an increasing number of lawsuits. Used to treat conditions such as deep vein thrombosis and pulmonary embolism, the blood thinner is also a popular preventative measure against strokes. Another, more broadcasted application for Xarelto is the prevention of blood clot formation in patients who have undergone knee or hip surgery, given their long periods of immobility.

Although it was initially heralded as a breakthrough, because it did not require extensive changes to diet, continuous monitoring or alteration in dosages, the drug has attracted a high level of scrutiny. The FDA has issued two black box warnings, which precede outright recall from the market. This is in response to unforeseen or undisclosed dangers associated with sudden cessation of a Xarelto regimen.

Since 2011, other studies have been conducted on the impacts of the drug. Patients switching from other blood thinner regimens had an increased rate of bleeding from the stomach and eyes, even when under a doctor’s supervision. This and similar complications resulted in more than 3,000 lawsuits against the drug’s manufacturers—Bayer AG and Janssen. In Louisiana, 2,800 suits were consolidated by the U.S. Judicial Panel for Multidistrict Litigation to form MDL No. 2592. Philadelphia’s Court of Common Pleas has similarly combined 550 separate suits as a mass tort program.

These lawsuits seek reparations from Janssen, a branch of Johnson and Johnson Corporation, and Bayer AG. The consolidated suits of MDL No. 2592 purport that Xarelto places individuals at increased risk of sudden and serious bleeding events. They also claim that the manufacturers used dishonest marketing tactics, concealing the risks from the public and promoting the positive attributes of the blood thinner.

Four bellwether trials of the drug will take place beginning in February of 2017. This follows extensive preparation in the months of December and January of 2015 and 2016, respectively. Further trial developments will be discussed in monthly status conferences.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010924